Roche acquires AMR focused 'Smarticles' technology company
This article was originally published in Scrip
Roche Holding AG has acquired GeneWEAVE BioSciences for up to $425m in order to get its hands on the latter''s "Smarticles" technology, which is being developed to help tackle the problem of antibiotic resistance.
You may also be interested in...
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.